SUMMIT ROCK ADVISORS LP
Q2 2022 Form 13-F

NEW YORK, NEW YORK
CIK 0001540951 · CRD 144059 · SEC-registered investment adviser
$122.4M Reported Value Total

SUMMIT ROCK ADVISORS, LP reports 185 total accounts under management (AUM). There are 140 discretionary accounts valued at $11,988,531,322, and 45 non-discretionary accounts valued at $9,744,767,193.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary & Non-Discretionary
Private funds (Form ADV)
25 funds · $15.2B gross asset value
Hedge Fund: $9.1B · Private Equity Fund: $6.1B
Source: Form ADV filed 2026-03-27
Reported value
$122.4M
Quarter over quarter
-9.5%
Holdings
8
Top-10 concentration
100.0%

Key People

Form ADV owners & control persons
David Allen Dechman
CHIEF EXECUTIVE OFFICER AND LIMITED PARTNER
Anne (nancy) Donohue
VICE CHAIR AND LIMITED PARTNER
William Russell Hedden
CHIEF OPERATING OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q2 2022 13F record

Q2 2022 13F filing summary

Q2 2022 Form 13F portfolio summary
Period of report June 30, 2022
Filed August 01, 2022
Form 13F-HR
Reported value $122.4M
Positions 8
Change in reported value -25.1%
New positions 1
Exited positions 1
Position turnover 22.2%
Top-10 concentration 100.0%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Oct 15, 2026
2 $47.0M
Q2 2026 13F
Filed Aug 4, 2026
3 $76.1M
Q1 2026 13F
Filed May 12, 2026
1 $16.0B
Q4 2025 13F
Filed Jan 27, 2026
1 $228.4K
Q3 2025 13F
Filed Nov 3, 2025
0 $0
Q2 2025 13F
Filed Aug 11, 2025
1 $355.4K
Q1 2025 13F
Filed May 9, 2025
2 $144.0M
Q4 2024 13F
Filed Feb 10, 2025
6 $294.9M
Q3 2024 13F
Filed Oct 30, 2024
6 $255.7M
Q2 2024 13F
Filed Jul 25, 2024
7 $323.5M
Q1 2024 13F
Filed May 8, 2024
9 $311.8M
Q4 2023 13F
Filed Jan 26, 2024
3 $216.9M
Q3 2023 13F
Filed Oct 24, 2023
3 $202.7M
Q2 2023 13F
Filed Jul 21, 2023
3 $206.1M
Q1 2023 13F
Filed May 9, 2023
2 $153.4M
Q4 2022 13F
Filed Jan 12, 2023
2 $146.8M
Q3 2022 13F
Filed Nov 2, 2022
5 $128.1M
Q2 2022 13F
Filed Aug 1, 2022
8 $122.4M
Q1 2022 13F
Filed May 6, 2022
8 $163.5M
Q4 2021 13F
Filed Feb 14, 2022
8 $167.4M

34 earlier quarters on file — choose one from the quarter menu above.

Top 8 holdings · Q2 2022

Largest Q2 2022 13F positions by reported value
# Holding Reported value % of portfolio
1 XLE SELECT SECTOR SPDR TR $60.3M 49.27%
2 IWN ISHARES TR $57.2M 46.72%
3 VT VANGUARD INTL EQUITY INDEX F $2.7M 2.18%
4 WMS ADVANCED DRAIN SYS INC DEL $671.0K 0.55%
5 DAWN DAY ONE BIOPHARMACEUTICALS I $593.0K 0.48%
6 CLOV CLOVER HEALTH INVESTMENTS CO $451.0K 0.37%
7 PHAT PHATHOM PHARMACEUTICALS INC $288.0K 0.24%
8 DYN DYNE THERAPEUTICS INC $240.0K 0.2%

Values as reported on the Q2 2022 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings